SLS - Latest News
SELLAS Life Sciences Group, Inc. (SLS), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $2.38B. Beta to the broader market is 2.49.
The article list below shows the most recent SLS headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent SLS Headlines
This One Data Readout Could Make Or Break Sellas Life Sciences Group
seekingalpha.com - Aug 13, 2026
SELLAS Life Sciences Group is a high-conviction buy ahead of the pivotal Phase 3 REGAL trial readout for GPS in AML. The unusually long REGAL trial t
SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com - Aug 11, 2026
- Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80 th Event - - 28 Patients En
SELLAS Life Sciences: The Ownership Structure Has Changed Before The Defining Catalyst
seekingalpha.com - Aug 2, 2026
SELLAS Life Sciences enters its pivotal REGAL readout with a transformed shareholder base, stronger balance sheet, and a new supply structure. Instit
SELLAS Life Sciences: Strong Buy-Imminent Catalyst, Dual-Platform Pipeline, And A Market That Hasn't Caught Up
seekingalpha.com - Jul 14, 2026
SELLAS Life Sciences is at the center of a debate over its event-driven Phase 3 REGAL trial for GPS in AML CR2 patients. The extended REGAL timeline
SELLAS Life Sciences Shares Slip Wednesday as Price Tests $16 Resistance Wall
benzinga.com - Jul 8, 2026
SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are trading lower Wednesday as investors take profits following the stock's strong longer-term uptr
How News Affects SLS Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track SLS's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked SLS news questions
- What is the latest SLS news headline?
- The most recent SLS headline (Aug 13, 2026) is "This One Data Readout Could Make Or Break Sellas Life Sciences Group". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the SLS news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What SLS news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual SLS options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.